# Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients

> **NCT02040415** · PHASE3 · COMPLETED · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 242 (actual)

## Conditions studied

- Acute Back Pain

## Interventions

- **DRUG:** DW-1030(eperisone HCl) 75mg
- **DRUG:** Myonal Tab.(eperisone HCl) 50mg
- **DRUG:** Placebo drug of DW-1030
- **DRUG:** Placebo drug of Myonal Tab.

## Key facts

- **NCT ID:** NCT02040415
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-07
- **Final completion:** —
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040415, "Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02040415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*